Supernus to Present at Cowen and Company Healthcare Conference in March
Cowen and Company 34th Annual Healthcare Conference
ROCKVILLE, Md. -- February 20, 2014
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical
company, today announced that the Company’s management will provide a business
update on the Company at the Cowen and Company Healthcare Conference.
Presentation Date: Monday, March 3
Time: 1:30pm ET
Place: The Boston Marriott Copley Place Hotel, Boston,
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Cockrell Group, 877-889-1972
Press spacebar to pause and continue. Press esc to stop.